Back
    Back

    Czech research seeks investors: New molecules could provide a breakthrough in the treatment of neurodegenerative diseases

    ConferenceProfessional Events Published on 02. 10. 2025 Reading time Reading time: 2 minutes
    Graphic banner with the Prague.bio conference logo

    At the Prague.bio international conference (open in a new window), neuroscientist Martin Horák, head of the Department of Neurochemistry, gave a lecture on the effects of new compounds acting on NMDA receptors (Antiepileptic effect of novel N-methyl-D-aspartate receptors antagonist). These substances show promising potential in the treatment of Alzheimer’s, Huntington’s and Parkinson’s diseases, epilepsy and other serious diseases associated with NMDA receptor dysfunction. The presentation of the research, which is being developed in collaboration with the University Hospital Hradec Králové, focused on connecting science with investors and opening the way to applied research.

    The conference took place on 25 September 2025 in Prague. Topics included innovation in drug development, diagnostics, medical technologies, the use of artificial intelligence, technology transfer, and legal and investment aspects of research and commercialisation. 

    We believe that the team will find a strong partner to help transform scientific results into real treatments for patients.

    Infomration

    Prague.bio Conference 2025 is a prestigious international conference for start-ups, R&D teams, investors and experts in the biotechnology industry, connecting key players in the Central European biotech community. It is organised by the Prague.bio (open in a new window) association with the aim of supporting technology transfer, innovation and investment in the Czech Republic and the entire region.